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Clopidogrel has been recently approved for treatment of non–ST-elevation acute coronary
syndromes based on the Clopidogrel in Unstable Angina to Prevent Recurrent Events
(CURE) trial. However, the trial’s findings are confounded by issues that lessen its clinical
significance. Clopidogrel did not reduce mortality; its benefit was limited to preventing
myocardial infarction, which was defined less stringently than in previous trials. Clopidogrel
led to an increase in major and minor bleeding. Furthermore, clopidogrel increased bleeding
risk in early cardiac surgery. Thus, widespread usage of clopidogrel, especially in centers with
an early revascularization strategy, will have limited clinical benefit with considerable risk.
(J Am Coll Cardiol 2002;40:218–9) © 2002 by the American College of Cardiology
Foundation
The presentation of the Clopidogrel in Unstable Angina to
Prevent Recurrent Events (CURE) trial at the 2001 Amer-
ican College of Cardiology (ACC) meeting was met with
overwhelming adulation. Labeled as a “blockbuster,” the
trial was reported on Cable News Network (CNN) within
1 h of presentation and described as one of the “most
significant advances for . . . acute coronary syndromes
(ACS) since aspirin” (1). Yet, amidst all the exuberance, a
simple question needs to be asked: is CURE, indeed, one of
the “most significant advances” for patients with ACS?
Assessing the significance of a trial statistically is straight-
forward—review the primary end point and its associated p
value. Clinical significance is, however, a far more complex
concept requiring an analysis of the relative merits of all end
points studied, a determination of the applicability of the
study population to one’s own patients and, finally, a
calculation of the incremental cost needed to achieve the
reported benefits. Increasingly, clinical trials are reporting
findings, which, although statistically significant, are not
necessarily clinically significant. We believe CURE provides
a telling illustration of this divergence.
CURE was, indeed, a positive trial; the combination of
aspirin and clopidogrel compared with aspirin alone reduced
the primary end point of cardiovascular death, myocardial
infarction (MI) and stroke (2). However, although the
individual end points of death, MI and stroke all show
numerical improvement with clopidogrel, the differences are
not statistically significant for death and stroke. Thus,
clopidogrel does not reduce mortality (2). It is simply not a
“life-saving” medication.
The reduction in the primary end point is driven by a
1.5% absolute reduction in the rate of subsequent nonfatal
MI (2). Although certainly a worthy end point, it is not
equivalent to a reduction in mortality. Furthermore, CURE
used a definition of MI, which included patients with only
elevated serum troponin levels. Therefore, an elevation of
serum troponin even in the absence of an elevation in
creatinine kinase levels would be considered sufficient to
meet the MI end point. This is in direct contrast with nearly
every other contemporary trial of ACS, which all use more
restrictive definitions requiring elevations in creatinine ki-
nase or its MB isoform (3–6). By using troponin, the extent
of myocardial necrosis prevented by clopidogrel may not be
as impressive as initially thought.
The most concerning complication noted with the addi-
tion of clopidogrel was an increased bleeding risk (1,2). The
rate of major bleeding increased by an absolute rate of 1%,
nearly half of which were defined as “life-threatening”. The
risk of transfusion of2 U of blood increased by an absolute
rate of 0.6%, and the risk of minor bleeding increased by an
absolute rate of 6.7%. Importantly, the definition of minor
bleeding underwent considerable revision between the ACC
presentation of the CURE trial data and its subsequent final
publication. These changes resulted in a dramatic reduction
in the reported rate of minor bleeding from 15.3% (when
presented) to 5.1% (in final manuscript). This modification
makes clopidogrel appear much safer than it really is. In fact,
the morbidity associated with major bleeding and the need
for blood transfusions may be as clinically significant as
preventing nonfatal MI when assessing the relative risks and
benefits of clopidogrel.
Yet, the most important concern of the CURE trial is
whether it can be applied to the American approach to
ACS. In contrast with Europe and Canada (origin of95%
of the CURE patients), the management of ACS in the
U.S. centers around rapid access to cardiac catheterization
and subsequent early percutaneous or surgical revasculariza-
tion in appropriate patients (7). The need for surgical
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revascularization in patients with ACS is considerable with
approximately 20% of patients having “surgical disease” (7).
Although CURE showed no significant excess of major
bleeding after coronary artery bypass grafting (CABG),
patients had clopidogrel withheld for a median of five days
before surgery (2). In countries outside the U.S., where the
median time to surgery after an ACS is more than 10 days,
this waiting period is inconsequential (7). Yet, in the U.S.,
the median time is less than four days (7). Therefore,
routine administration of clopidogrel to all patients with
ACS will expose the surgical subset to either an excessive
bleeding risk with surgery or significant delays in undergo-
ing surgery. These concerns regarding excess bleeding and
delays are not theoretical. Among patients in CURE who
stopped clopidogrel less than five days before CABG, the
incidence of major bleeding increased by an absolute rate of
3.3% (2). Furthermore, a number of reports have docu-
mented an increased transfusion requirement and a four- to
10-fold increased risk of surgical reexploration for postop-
erative bleeding in patients who underwent CABG within
three days of clopidogrel administration (8–10).
These are not trivial risks. If clopidogrel is administered
to 1,000 patients with ACS to prevent 15 nonfatal MIs, 10
additional patients develop major bleeding, 69 additional
patients have minor bleeding, and 200 patients have surgical
decisions complicated by its administration. In addition,
978 patients taking clopidogrel derive no significant benefit
from this drug, and all of this occurs without saving one life.
Proponents argue that widespread use of clopidogrel
could prevent “50,000 to 100,000 heart attacks, strokes, or
deaths” in North America and “250,000 to 500,000 events”
worldwide based on the CURE results (1). However, it is
important to understand that attainment of these benefits
would require administration of clopidogrel to approxi-
mately 2.3 million to 4.6 million patients in North America
alone and approximately 11.5 million to 22.7 million pa-
tients worldwide. At $3 per tablet, the absolute costs
involved are approximately $2 billion to $4 billion in North
America and $10 billion to $20 billion worldwide.
Other examples of divergent statistical and clinical find-
ings abound. In ACS, should all patients receive “upstream”
IIb/IIIa inhibitors when the clinical benefit is limited to
those who undergo percutaneous intervention (11,12)? In
out-of-hospital cardiac arrest, is an increase in survival to
hospitalization with amiodarone clinically significant if
there is no improvement in survival to hospital discharge
(13)? To truly advance the medical care of our patients, our
adoption of clinical trial results should be based on their
clinical significance rather than solely an impressive p value.
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Abbreviations and Acronyms
ACC  American College of Cardiology
ACS  acute coronary syndrome
CABG  coronary artery bypass grafting
CURE  Clopidogrel in Unstable Angina to Prevent
Recurrent Events trial
MI  myocardial infarction
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